• Explore /
  • Poster
  • / Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).

Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).

Abstract Poster

Authors

Jose Villasboas

Jose Caetano Villasboas

Division of Hematology, Mayo Clinic, Rochester, MN

Jose Caetano Villasboas , Justin Paul Kline , Aleksandr Lazaryan , Nancy L. Bartlett , Francisco J. Hernandez-Ilizaliturri , Farrukh Tauseef Awan , Praveen Ramakrishnan Geethakumari , Reem Karmali , Leyla Shune , Frederick Lansigan , Craig B. Reeder , Catherine S. Magid Diefenbach , Elad Sharon , Pamela J. Atherton , Jack Fiskum , Jun Yin , Alex A. Adjei , Stephen M. Ansell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03038672

Citation

J Clin Oncol 40, 2022 (suppl 17; abstr LBA7564)

DOI

10.1200/JCO.2022.40.17_suppl.LBA7564

Abstract #

LBA7564

Poster Bd #

217

Abstract Disclosures

Similar Posters

First Author: Jose Caetano Villasboas

First Author: Dok Hyun Yoon

First Author: Brian T. Hess

First Author: Koichi Azuma